Search

Displaying results 1701 - 1710 of 10000 in total
  1. Drug

    Velmanase alfa

    go.drugbank.com/drugs/DB12374
    ApprovedInvestigational

    Patients with alpha-mannosidosis have a genetic mutation that causes a deficiency in the lysosomal enzyme alpha-mannosidase, which is an enzyme responsible for breaking down complex sugars in the body. … Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder.

  2. Drug

    Uridine triacetate

    go.drugbank.com/drugs/DB09144
    Approved

    As a result, these metabolites are associated with various unpleasant side effects such as neutropenia, mucositis, diarrhea, and hand–foot syndrome. … As a result of UMPS deficiency, patients experience a systemic deficiency of pyrimidine nucleotides, accounting for most symptoms of the disease.

  3. Drug

    Xylitol

    go.drugbank.com/drugs/DB11195
    ApprovedInvestigational

    It is widely used as a sugar substitute and in "sugar-free" food products. … Xylitol is a non-fermentable sugar alcohol by most plaque bacteria, indicating that it cannot be fermented into cariogenic acid end-products [A32423].

    Mixtures: Fluor-a-day, Fluor-a-dayCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Medical air

    go.drugbank.com/drugs/DB09337
    ApprovedInvestigationalVet approved

    Medical air is supplied by a special air compressor to patient care areas using clean outside air.

  5. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    [L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl … Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    Doxecitine is currently approved and marketed as a fixed-dose combination therapy with [thymidine] (KYGEVVI). … Doxecitine is a synthetic form of the naturally occurring pyrimidine deoxyribonucleoside deoxycytidine.

  7. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [L44537] Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain [A253947,A253952] with high selectivity to Aβ protofibrils. … Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology

  8. Drug

    Delafloxacin

    go.drugbank.com/drugs/DB11943
    ApprovedInvestigational

    Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections,

    Categories: Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP3A Inducers
  9. Drug

    Atirmociclib

    go.drugbank.com/drugs/DB21733
    Investigational

    Atirmociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Atirmociclib is a cyclin dependant kinase inhibitor. … Atirmociclib has a monoisotopic molecular weight of 463.18 Da.

  10. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. … [L149] In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic